Long-term therapeutic response to dupilumab in patients affected by prurigo nodularis: A real-world retrospective study

Scarce data related to the clinical effectiveness of dupilumab in patients with chronic prurigo nodularis (CPN) have been reported in a real-world setting.1,2 We retrospectively analysed clinical and demographic features of 64 adult patients affected by CPN who underwent systemic treatment with dupilumab, assessing long-term effectiveness and safeness of dupilumab (Table 1). Prior to starting dupilumab, 75% of patients showed a high disease burden, with moderate-to- severe skin manifestations (investigator global assessment [IGA]-CPN staging: 3–4), severe itch (mean itch-numeric rating scale (itch-NRS): 8.8 ± 1.1), excoriation in at least 26% of total CPN lesions (IGA-CPN activity score: 3–4)3 in 71.9% of patients (Table 2), marked impairment of patients' quality of life (mean dermatology life quality index [DLQI] score: 22.7 ± 4.8) and sleep disturbances (mean sleep-NRS score: 8.2 ± 1.6).